Oei, Shiao Li http://orcid.org/0000-0002-5772-550X
Thronicke, Anja http://orcid.org/0000-0002-6421-8290
Matthes, Harald http://orcid.org/0000-0002-4053-4379
Schad, Friedemann http://orcid.org/0000-0002-6928-6209
Article History
Received: 27 February 2020
Accepted: 7 July 2020
First Online: 15 July 2020
Compliance with ethical standards
:
: HM is a member of the board of directors of Weleda AG and a member of the Network Arbeitsgemeinschaft der Wissenschaftlichen Fachgesellschaften (AWMF e.V.) guideline committee for integrative oncology (Guideline for Complementary Medicine in the Treatment of Oncological Patients). HM has an endowed professorship at the Charité Universitätsmedizin Berlin, which is financed by the Software AG Foundation, outside the submitted work. FS reports grants from Helixor Heilmittel GmbH (travel costs and honoraria for speaking), grants from AstraZeneca (travel costs and honoraria for speaking), grants from Abnoba GmbH, and grants from Iscador AG, outside the submitted work. The other authors have declared that no competing interests exist. No payment was received for any other aspects of the submitted work. There are no patents, products in development or marketed products to declare. There are no other relationships/conditions/circumstances that present a potential conflict of interest.
: The study complies with the principles laid down in the Declaration of Helsinki. The Network Oncology (NO) study has been approved by the ethics committee of the Medical Association Berlin (Berlin–Ethik-Kommission der Ärztekammer Berlin). The reference number is Eth-27/10. This study had been retrospectively registered at the WHO approved register German Register for Clinical Trials (Deutsches Register Klinischer Studien, DRKS), trial registration number DRKS00013335 on 27/11/2017.
: Written informed consent has been obtained from all patients prior to study enrollment.
: Not applicable